FDA, Uninvited To Congress’ PCAST Hearing, Blogs Its Accomplishments
Woodcock says “critical challenges” remain on implementing recommendations of President’s Council, but timing of statement could be signal to Congress: be careful what else you put on our plates.
You may also be interested in...
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.